Biomodal, an omics-based life sciences technology and analytics company, announced today that it will present new data showcasing the effectiveness of its duet multiomics solution, evoC, in the early detection of diseases. This solution differentiates between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) to enhance signal detection. According to a recently submitted preprint, the 6-base genome—comprising A, T, G, C, 5mC, and 5hmC—allows for the observation of increased 5hmC signals in the early stages of disease, occurring before the reduction of 5mC in later stages.
Methylation and demethylation are critical processes that regulate gene expression throughout development and disease. Methylation (5mC) effectively silences genes, while demethylation (the conversion of 5mC to 5hmC and then to cytosine) activates them. Traditional measurements of methylation have grouped 5mC and 5hmC into a single modified cytosine signal (modC), obscuring the demethylation pathway from 5mC to 5hmC during early disease stages. These groundbreaking findings will be presented at the ASHG annual meeting in Denver on November 6, 2024.
“Our goal is to equip researchers and developers of liquid biopsy tests with innovative tools that uncover previously undetectable biological changes,” said Peter Fromen, CEO of biomodal. “The preprint data indicates that the 6-base genome serves as a powerful discovery tool for observing shifts in gene regulation through 5mC and 5hmC biomarkers, potentially enhancing early disease detection. While our research focused on colorectal cancer, we believe these insights are relevant for early detection and monitoring across various conditions, not just in oncology.”
Details of the study can be found in the preprint available on bioRxiv.org.
In addition to their findings on cancer detection, the company will also showcase data on the predictive capabilities of the 6-base genome regarding gene regulation, along with new developments in single-cell methodologies for 6-base analysis.
Oral Presentation:
- Title: 5-methylcytosine and 5-hydroxymethylcytosine as synergistic biomarkers for early detection of colorectal cancer
- Date: Wednesday, November 6, 2024
- Time: 12:00 PM – 1:00 PM
- Location: RM103
Poster Sessions:
- Title: Multiomic 6-base data from cell-free DNA enhances the performance of liquid biopsy classifiers
- Date: Wednesday, November 6, 2024
- Time: 2:30 PM – 4:30 PM MT
- Location: Exhibit & Poster Hall, Hall F, Board 8050W
- Title: Simultaneous single-cell sequencing of genetic and epigenetic bases
- Date: Thursday, November 7, 2024
- Time: 2:30 PM – 4:30 PM MT
- Location: Exhibit & Poster Hall, Hall F, Board 1170T
- Title: Inferring genome organization and gene regulation from 6-base sequencing data
- Date: Friday, November 8, 2024
- Time: 2:30 PM – 4:30 PM MT
- Location: Exhibit & Poster Hall, Hall F, Board 1021F
About biomodal
Biomodal is an omics-based life sciences technology and analytics company focused on making the dynamic nature of biology clear and accessible. Our duet multiomics solutions provide rich epigenetic information from a single, low-input DNA sample without requiring complex bioinformatics or harsh chemicals. Our single-base-resolution sequencing approach combines genetic and epigenetic data, yielding greater biological insights in areas such as cancer, neurodegenerative diseases, and aging.
